+38 (044) 365-07-90 mcb@im-group.com.ua
UA EN
Eurobio Scientific Available to order

The Prolaris® Predictive Test for Prostate Cancer

Prolaris® is a gene expression test that accurately measures the activity of specific genes that influence tumor growth and allows for clear conclusions regarding the tumor’s prognosis.

0 reviews 0 questions

Directions

Industries

Oncology and personalised medicine Clinical laboratory diagnostics

Methods

Real-time PCR

Type

Reagents

Turnkey supply, installation and training · Service across Ukraine

Low gene activity is associated with a lower risk of tumor progression. Conversely, high activity is associated with a higher risk.

On their own, traditional prognostic factors, such as PSA levels and the Gleason score, are not accurate enough to predict how the cancer will progress. Prolaris® measures the activity of cell cycle progression (CCP) genes to determine how prostate cancer is behaving now and will behave in the future. 

  • It is the only test with validated thresholds for active surveillance and multimodal treatment in untreated patients
  • Provides accurate risk stratification by combining PSA (prostate-specific antigen) and the Gleason score with an independent assessment of gene expression based on cell cycle progression (CCP)
  • Suitable for testing RNA samples from formalin-fixed, paraffin-embedded (FFPE) tumor tissue obtained from both biopsies and surgical specimens
  • Compatible with the QuantStudio™ 5 Dx real-time PCR system (Thermo Fisher Scientific) 
  • The test is approved for diagnostic use and holds a Certificate of Conformity for in vitro diagnostic (IVD) medical devices in the European Economic Area (CE-IVD)

Order The Prolaris® Predictive Test for Prostate Cancer

We will pick the configuration and prepare the request

Leave a request and our specialist will contact you and prepare a first proposal.

Send a request